Tempus AI (TEM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling

Tempus AI: Less Risky Than When I Said Buy

Tempus Expands Strategic Collaboration with Bristol Myers Squibb

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer's Disease and Other Neurological Conditions

Tempus AI: Moderna's New Cancer Vaccine Partner Is The Pick Of The AI Biotech Bunch